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Abstract
Background: Manipulation of the immune system represents a promising avenue for cancer therapy. Rational advances in
immunotherapy of cancer will require an understanding of the precise correlates of protection. Agonistic antibodies against
the tumor necrosis factor receptor family member 4-1BB are emerging as a promising tool in cancer therapy, with evidence
that these antibodies expand both T cells as well as innate immune cells. Depletion studies have suggested that several cell
types can play a role in these immunotherapeutic regimens, but do not reveal which cells must directly receive the 4-1BB
signals for effective therapy.
Methodology/Principal Findings: We show that re-activated memory T cells are superior to resting memory T cells in
control of an 8-day pre-established E.G7 tumor in mice. We find that ex vivo activation of the memory T cells allows the
activated effectors to continue to divide and enter the tumor, regardless of antigen-specificity; however, only antigen-
specific reactivated memory T cells show any efficacy in tumor control. When agonistic anti-4-1BB antibody is combined
with this optimized adoptive T cell therapy, 80% of mice survive and are fully protected from tumor rechallenge. Using 4-
1BB-deficient mice and mixed bone marrow chimeras, we find that it is sufficient to have 4-1BB only on the endogenous
host ab T cells or only on the transferred T cells for the effects of anti-4-1BB to be realized. Conversely, although multiple
immune cell types express 4-1BB and both T cells and APC expand during anti-4-1BB therapy, 4-1BB on cells other than ab T
cells is neither necessary nor sufficient for the effect of anti-4-1BB in this adoptive immunotherapy model.
Conclusions/Significance: This study establishes ab T cells rather than innate immune cells as the critical target in anti-4-
1BB therapy of a pre-established tumor. The study also demonstrates that ex vivo activation of memory T cells prior to
infusion allows antigen-specific tumor control without the need for reactivation of the memory T cells in the tumor.
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Introduction
Despite extensive evidence that CD8 T lymphocytes can recognize
and kill cancer cells, malignant tumors are rarely controlled by
spontaneous immune responses [1]. Thus there is great interest in
manipulating CD8 T cells to enhance their ability to seek out and kill
tumor cells. Adoptive T cell therapy, in which autologous cells from
the patient are expanded ex vivo and reintroduced into the patient,
represents a promising approach for activating the immune response
against cancer [1,2]. However, further optimization of these
approaches will require an understanding of the cell types and
mechanisms required for tumor control in an immunotherapeutic
context.
One approach to enhancing CD8 T cell-based cancer therapy is
to use immune modulators targeting T cell survival and effector
pathways. The TNFR family member 4-1BB is a potent survival
factor for activated and memory CD8 T cells [3–9]. 4-1BB is
superior to CD28 in expanding T cells for adoptive therapy [10]
and 4-1BBL-expanded CD8T cells have increased effector function
percell[10,11].Thus4-1BBagonistsrepresentattractivecandidates
for combination therapy with adoptively transferred CD8 T cells.
Since the initial observation that agonistic anti-4-1BB antibodies
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11003promote tumor regression in mice [12], a large number of studies
have shown efficacy of 4-1BB stimulation in anti-cancer therapies
(Reviewed in [13,14]). Indeed phase I trials are underway using
humanized anti-4-1BB agonist antibodies for advanced cancers
(reviewed in [14]). To further improve these therapies in a rational
way, it will be important to understand the cellular targets involved
in the response to anti-4-1BB therapy [15].
Another key issue for optimization of adoptive T cell therapy has
been to determine the most efficacious T cell subset for the
eradication of tumors in vivo. CD8 T cells can display an ‘‘effector’’,
‘‘effector memory’’, or a ‘‘central memory’’ phenotype [16]. A
recent report suggests that reactivation of effector memory T cells
prior to adoptive transfer removes the need for additional
immunization during adoptive T cell therapy, resulting in effective
tumor control following in vitro programming of the T cells [17].
Whereas primary effector or effector memory CD8 T cells are
superior in target killing, central memory CD8 T cells have a
survival advantage [16]. CD8 T cells expanded in IL-15 have a
survival advantage over IL-2 generated CD8 effector T cells [18]
and IL-15 induced central memory cells show more effective tumor
control than IL-2 generated effector T cells [19–21]. Consistent
withthis hypothesis, persistenceof transferred T cellscorrelateswith
cancer regression in an adoptive T cell therapy trial of metastatic
melanoma[22]. As effectorcells reactivated from centralmemory T
cells show more persistence than effectors obtained from effector
memory T cells after transfer into macaques [23], these cells appear
to be the preferred subset for adoptive therapy.
Here we demonstrate that effector T cells reactivated from
central memory T cells (‘‘reactivated memory’’) are indeed more
efficacious in tumor control than resting central memory T cells
(‘‘resting memory’’) against an established tumor. We then took
this optimized T cell therapy model and combined it with in vivo
treatment with agonistic anti-4-1BB antibodies. T cells reactivated
from ovalbumin-specific OT-I memory T cells together with anti-
4-1BB agonistic antibody resulted in 80% tumor free survival in
mice bearing 6–9 mm pre-established tumors. We next went on to
determine the mechanism of action of 4-1BB in this model.
Cell depletion studies have implicated a number of cell types in
tumor therapy with anti-4-1BB [12,24–29]. However, while such
studiesindicatewhichcellsinthehostarerequiredfortumorcontrol,
they do not reveal the direct therapeutic targets of anti-4-1BB.
Systemic administration of anti-4-1BB agonistic antibody at doses of
aslittleas 200 mg/mouse has been shown tocausesplenomegalyand
other immune system anomalies [30], therefore it is essential to
determine the important targets of anti-4-1BB for tumor control so
that more focused therapies can be devised to potentially avoid
immunotoxicity. In this report we used 4-1BB-deficient mice and
bone marrow chimeras to address this issue. Despite the efficacy of
anti-4-1BB in expanding innate immune cells, as well as host T cells,
we found that 4-1BB on the transferred T cells or on the host ab T
cells is necessary and sufficient for the effects of anti-4-1BB on
adoptive tumor therapy against the E.G7 thymoma. Conversely,
expression of 4-1BB on cells other than ab T cells is neither
necessary nor sufficient for the effect of 4-1BB agonists even when
the transferred T cells lack 4-1BB. These studies pinpoint T cells
rather than innate immune subsets as the major target of 4-1BB
agonists in cancer therapy against this rapidly growing thymoma.
Results
Reactivated memory CD8 T cells manifest superior anti-
tumor activity compared to resting memory T cells
To test the role of 4-1BB in an adoptive therapy model, we first
set out to optimize the adoptive therapy using in vitro generated
memory T cells. To generate a large number of Ag-experienced
OT-I T cells in vitro, OT-I splenocytes were cultured with peptide
Ag followed by IL-15, resulting in a 20- to 30-fold expansion of the
T cells by day 9 (data not shown). OT-I T cells generated in IL-15
displayed a resting ‘‘central memory’’ phenotype as indicated by
their high surface expression of CD44 and CD62L with low to
undetectable CD69 and 4-1BB expression (Fig. 1A). Reactivated
memory T cells were generated by stimulating the IL-15-expanded
memory T cells with irradiated peptide-loaded syngeneic spleno-
cytes for 2 days prior to transfer. Reactivated memory T cells
markedly up-regulated 4-1BB and CD69 expression, while
modestly down-regulating CD62L (Fig. 1A). The reactivated
memory T cells exhibited a 50–80% greater cytotoxicity against
E.G7 targets than the resting memory T cells (Fig. 1B). It should
be noted that the rapid reactivation of effector function of these in
vitro generated ‘‘central memory’’ cells, supports the contention
that they have acquired the properties of memory cells, as
restimulation of primary effectors results in activation induced cell
death [31,32].
To test the efficacy of resting versus reactivated memory T cells
in vivo, three million OT-I cells were injected intravenously (i.v.)
into mice bearing E.G7 tumors. This cell number/body weight
ratio was relevant to clinical doses for adoptive cancer therapy
[33]. Animals were inoculated with E.G7 tumor cells either one
day (Fig. 1C left panel) or 8 days before T cell transfer (Fig. 1C
right panel). A subcutaneous E.G7 tumor grew rapidly in
untreated C57BL/6 mice, reaching 6–9 mm in diameter by one
week after inoculation. Untreated animals succumbed to a large
progressive tumor (+/2 20620 mm) in 2–4 weeks. When OT-I T
cells were administered, a delay in tumor growth was observed.
Reactivated memory T cells were more potent than resting
memory cells based on adoptive transfer of the same number of T
cells in both the 1-day tumor and 8-day tumor settings, although
the effect was more pronounced in the small tumor setting. The
fate of the tumor bearing animals was followed for up to 100 days.
Using reactivated memory T cells, 63% or 33% of animals were
tumor-free in the small or large tumor setting, respectively. When
resting memory cells were injected, only 25% of mice in the small
tumor group and 8% in the large tumor group were tumor free by
day 100. Thus, reactivated memory CD8 T cells were more potent
than resting memory cells in this model of adoptive T cell therapy.
Subsequent experiments were performed using the more stringent
8-day tumor setting.
It was possible that the reactivated effectors were more potent
than resting memory T cells in controlling the tumor due to the
effect of transferring pre-activated T cells which might result in
Ag-non-specific tumor regression due to their cytokine production.
Therefore, in a parallel set of experiments we compared
reactivated memory T cells from OT-I mice with those obtained
from P14 TCR transgenic mice, specific for LCMV glycoprotein
gp33–41 [34]. Reactivated memory OT-I and P14 T cells showed a
similar surface phenotype (Fig. 2A). However, only the reactivated
OT-I memory T cells showed any efficacy in tumor control
(Fig. 2B and C). Thus reactivated memory T cells control tumor
growth in an antigen-specific fashion.
Analysis of adoptively transferred resting and reactivated
memory CD8 T cells in tumor bearing animals
We next examined the primary tumor, draining lymph node
and spleen for the congenically marked Thy1.1 OT-I T cells at
day one, four and seven after transfer (Fig. 3A, B). Distinct in vivo
kinetic patterns were noted for resting memory and reactivated
memory OT-I cells. As shown in figure 3A, 0.7260.12610
6
Thy1.1 positive cells were recovered in the spleen, constituting
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contrast, reactivated memory cells were nearly undetectable
(0.0460.004610
6 in the spleen) at this time point (1 day post-
transfer). However, a remarkable increase of Thy1.1 positive cells
was observed 3 days later in the tumor, DLN and spleen of mice
that received reactivated memory T cells. The increased OT-I cell
accumulation was most striking in the tumor, in which a .100-
fold increase in percentage and .30-fold in total number of
Thy1.1 positive cells were recorded. The rapid cell division by
reactivated memory OT-I cells following adoptive transfer was
Figure 1. Superior anti-tumor activity of reactivated compared to resting memory T cells. (A) Phenotypes of naı ¨ve, in vitro generated
resting and reactivated OT-I memory cells. OT-I cells were surface stained for the expression of CD44, CD62L, CD69 and 4-1BB (open areas), overlaid
on the background staining with isotype controls (shaded areas). Histograms were gated on the CD8
+ population. (B) In vitro killing of E.G7 target
cells by resting or reactivated memory OT-I cells. The cytotoxicity of resting and reactivated memory OT-I cells was tested on day 9 of culture, in a 4-
hour Cr
51 release assay at the indicated effector to target ratios. Parental (ovalbumin negative) EL-4 cells were used as a negative control. (C) Adoptive
immunotherapy of E.G7 tumor bearing animals with reactivated or resting memory OT-I cells. Mice were inoculated s.c. with E.G7 cells on day 0. One
day (left panel) or eight days (right panel) later, tumor-bearing mice received 3610
6 OT-I resting memory or reactivated memory cells i.v. or no cell
transfer, as indicated. Average tumor growth, the number (n) of mice per group and survival of tumor bearing mice are shown. Tumor growth curves
were discontinued at the time when the first animal in the group succumbed to the disease. Results are pooled from two independent experiments.
Survival curves were analyzed by the LogRank test, with *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0011003.g001
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Active expansion was evident for the reactivated memory OT-I
cells between one to seven days following adoptive transfer, as
reflected by an increased frequency of Thy1.1 cells in the
regressing primary tumors, DLN and spleen, as well as an
increased/sustained total number of Thy1.1 cells in the DLN and
spleen (Fig. 3A). Concomitantly, tumor regression occurred in the
majority of animals treated with reactivated memory T cells
(Fig. 1C). In contrast, despite their initial high recovery on day 1
the adoptively transferred resting memory T cells expanded poorly
in the spleen and DLN and their percentage and number declined
in all the tissues/organs examined (Fig. 3A, B).
We examined the adoptively transferred cells for evidence of
activation by measuring surface markers of activation on Thy1.1
positive cells. Whether the mice had received resting or reactivated
memory cells, the OT-I cells recovered from the tumor showed an
activated T cell phenotype with low CD62L expression and high
levels of CD69 and 4-1BB (Fig. 3B). Both T cell populations in the
tumor also displayed IFN-c producing capability (data not shown).
Thus, cells that have entered the tumor have an activated
phenotype regardless of their starting phenotype.
Analysis of activation markers as well as CFSE staining of
transferred cells in the DLN and spleen indicated that the resting
memory cells were less activated and had undergone fewer
divisions than the effector cells derived by reactivation of memory
T cells. In general, there was less activation and less evidence of
division in the DLN and spleen than in the tumor for both kinds of
transferred T cell (Fig. 3B).
The above studies show that reactivated memory T cells divide
substantially more than resting memory T cells after transfer into
the tumor-bearing host in both the tumor as well as in the
secondary lymphoid organs. Previous studies have shown that
CD8 T cells exposed to antigen ex vivo for a brief period are
committed to undergo several rounds of division in the absence of
the continuous presence of antigen [35–37]. Thus the expansion of
reactivated memory T cells in vivo could be due to continued
division after stimulation ex vivo, or due to re-encounter with Ag in
vivo. To distinguish these possibilities, we conducted a similar
experiment comparing CFSE-labeled reactivated P14 or OT-I
memory T cells. By day 4, both P14 and OT-I T cells in all organs
were CFSE negative (data not shown), indicating that they had
undergone extensive division. However, by day 8, there were
fewer transferred T cells found in the tumor of mice that had
received OT-I compared to those that had received P14 T cells
(Fig. 3C), likely reflecting that the OT-I T cells have already
started to destroy the tumor by this point, whereas with the P14
transferred mice, the T cells have no effect on tumor growth
(Fig. 2B). Thus, the ability to enter the tumor and continue to
divide appears to be a property of the ex vivo activation of the T
cells rather than a result of the T cells specifically encountering
antigen in vivo and tumor infiltration of activated T cells does not
necessarily correlate with protection. This result suggests that,
even in the relatively immunogenic E.G7 model, the tumor
microenvironment is still unfavorable or suppressive for optimal
activation of adoptively transferred memory T cells. The use of ex
vivo reactivated memory T cells allows the T cells to expand in
Figure 2. Antigen specificity of tumor control by reactivated memory T cells. (A) Phenotypes of in vitro generated reactivated OT-I and P14
memory cells. T cells were surface stained for the expression of CD44, CD62L and CD69 (open areas) overlaid on the background staining with isotype
controls (shaded areas). Histograms were gated on the CD8
+ population. (B) Mice bearing eight-day E.G7 tumors were given 3610
6 reactivated OT-I
or P14 memory cells i.v. or no cell transfer, as indicated. Average tumor growth is shown for two independent experiments, with (n) indicating
number of mice per group. Tumor growth curves were discontinued at the time when the first animal in the group succumbed to the disease. (C)
Survival data for tumor bearing mice were pooled from two independent experiments. Survival curves were analyzed by the LogRank test, with
***P,0.001.
doi:10.1371/journal.pone.0011003.g002
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PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11003Figure 3. Analysis of memory OT-I cells after adoptive transfer into tumor bearing animals. C57BL/6 mice were inoculated s.c. with E.G7
tumor cells on day 0. On day 8, resting memory or reactivated memory OT-I cells were transferred into tumor bearing mice. On day 1, 4, or 7, mice
were sacrificed and OT-I Thy1.1 cells were enumerated in the tumor, draining lymph node (DLN) and spleen. (A) The percentage of OT-I resting
memory and reactivated memory cells was determined according to gated CD8
+ Thy1.1
+ cells over the total number of living cells. The OT-I cell
number was obtained by multiplying the percentage by the total cell count of the organ. A summary of two independent experiments is shown. (B)
Histograms show the expression of CD62L, CD69 and 4-1BB (open area) overlaid on the background staining with antibody isotype controls (shaded
4-1BB in T Cell Tumor Therapy
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problem of needing to reactivate the memory T cells within the
tumor.
Effect of agonistic anti-4-1BB on adoptive therapy with
reactivated memory T cells
Although reactivated memory OT-I cells were more effective in
treating an established cancer as compared to resting memory
OT-I cells, in this stringent 8-day E.G7 tumor model only about
30% of tumor bearing mice remained tumor-free for 100 days
after tumor onset (Fig. 1). Therefore, it was of interest to determine
whether the response obtained with reactivated memory T cells
could be improved by a combined therapy with anti-4-1BB. In
addition to showing better tumor control, the reactivated effectors
also express higher levels of 4-1BB than the resting memory T cells
(Fig. 3B) and therefore should be more responsive to anti-4-1BB
therapy.
We chose a dose of 100 mg/mouse of anti-4-1BB delivered at day
0 and 3 after T cell transfer, based on previous studies showing
efficacy of anti-4-1BB at this dose [12]. Administration of agonistic
anti-4-1BB antibody alone induced complete tumor regression in
57% of animals while all animals in the control group succumbed to
a progressive cancer within 50 days (Fig. 4A). When the anti-4-1BB
antibody was used together with adoptive transfer of reactivated
memory T cells, tumor rejection was achieved in 79% of animals as
compared to a 36% tumor rejection rate in mice that received only
adoptive T cell transfer (Fig. 4A). Although the combined therapy
did not show a statistically significant difference over anti-4-1BB
alone (p=0.18), the addition of anti-4-1BB to the adoptive transfer
model consistently increased the number of surviving mice
compared to rat IgG control, in this and subsequent experiments.
Of note, all mice that received reactivated T cells and anti-4-1BB
survived the initial tumor were also resistant to subsequent tumor
challenge (supplementary Figure S1).
Anti-4-1BB enhances the expression of markers of
survival and CTL effector function in reactivated memory
T cells
The T cells used for adoptive transfer in this study are highly
activated with potent CTL function (Fig. 1B). Nevertheless, we
asked whether anti-4-1BB could further enhance their activation.
Figure 4B shows that reactivation of memory T cells with peptide
and control antibody leads to maximal activation as measured by
CD69, CD44 and 4-1BB expression, as there is no further
enhancement with addition of anti-4-1BB to the cultures. In
contrast, the addition of anti-4-1BB to the memory T cells during
their reactivation leads to increases in the survival marker Bcl-xL
as well as increases in granzyme B, a marker of CTL function
(Fig. 4C–E). Thus, remarkably, anti-4-1BB can further activate
even these highly stimulated reactivated memory T cells. To
further investigate whether anti-4-1BB-mediated enhanced effec-
tor function was specific to reactivated memory cells, naı ¨ve CD8 T
cells were stimulated with Ag under same conditions in the
presence of anti-4-1BB. Compared to the robust granzyme B
induction with anti-4-1BB on reactivated memory cells, anti-4-1
BB was found to have a minimal effect in enhancing granzyme B
expression on primary effectors derived from naı ¨ve CD8 OT-I
(Fig. 4F). This result adds further impetus to the decision to use
effectors reactivated from memory T cells, rather than primary
effectors for the combined therapy with anti-4-1BB.
Anti-4-1BB therapy expands innate immune cell subsets
as well as endogenous and transferred T cells
A number of studies have used immunodepletion of different
immune cell subsets to elucidate the cellular targets of 4-1BB in a
tumor therapy setting. Depending on the particular model, CD8,
CD4, DC and NK cells have all been implicated in anti-4-1BB
therapies of cancer based on such immunodepletion studies prior
to treatment [12,24–29,38]. Moreover, 4-1BB signaling has been
shown to enhance dendritic cell and NK cell function [39–42].
While such experiments show that tumor control can require the
interplay between different immune subsets, their complete
deletion does not distinguish between anti-4-1BB agonists acting
directly on these populations or a 4-1BB-independent requirement
for these subsets in tumor control. Therefore, we evaluated the
effect of anti-4-1BB on different immune subsets following
adoptive therapy with OT-I T cells in vivo. The endogenous T
cells were distinguished from transferred T cells by their lack of
Thy1.1 expression. Compared to control rat IgG, anti-4-1BB
increased the number of endogenous CD4 and CD8 T cells in the
spleen and DLN of the mice. Moreover, transferred OT-I T cells
also increased in number in the DLN upon anti-4-1BB treatment,
but only if they expressed 4-1BB (Fig. 5, bottom panel). However,
we did not see an increase in total T cell numbers in the tumor,
perhaps because in the anti-4-1BB treated group, the tumor
regresses rapidly and the T cells are no longer retained. In addition
to effects on T cells, anti-4-1BB also increased the number of
CD11c
hi and CD11c
int CD8-negative populations in spleen and
DLN, indicating an effect on host dendritic cells and macrophages
(Fig. 5). Again, significant effects of anti-4-1BB on the cells
infiltrating the tumor were not seen. We also examined
NK1.1
+CD8
2CD3
+ and NK1.1
+CD3
2 cells, but the enhance-
ment of NK1.1
+ cell numbers was seen in only one of three
experiments (data not shown).
4-1BB on the transferred T cells or on host cells is
sufficient for the anti-tumor effect of anti-4-1BB
The above data indicated that anti-4-1BB therapy increases the
numbers of innate immune cells, such as dendritic cells, as well as
having effects on recovery of endogenous and transferred T cells.
Thus it was of interest to determine which of these cell populations
were important in the therapeutic response to anti-4-1BB.
Therefore, we transferred reactivated memory cells together with
anti-4-1BB into WT and 4-1BB-deficient tumor bearing hosts
(Fig. 6A). The results show that 4-1BB in the host is completely
dispensable for tumor control and mouse survival in response to
the anti-4-1BB therapy in this combined adoptive T cell therapy
model. Thus 4-1BB on the adoptively transferred T cells is
sufficient to mediate the effect of anti-4-1BB in this adoptive
immunotherapy model.
area) on ex vivo resting memory and reactivated memory OT-I Thy1.1
+ cells in tumor bearing mice 4 days after adoptive transfer. The lower panel
shows the proliferation of CFSE labeled OT-I Thy1.1 cells four days after transfer. Similar results were obtained from two independent experiments
with 3 mice per group. (C) Reactivated OT-I or P14 memory cells were labeled with CFSE and adoptively transferred to 8 day-tumor bearing mice as in
Figure 2B, C. Recovery of the reactivated memory cells was analyzed on day 4 and 8 following adoptive transfer. Day 4 results are representative of
two experiments, and the day 8 results were obtained in one experiment, with 2–5 mice per group per time point. By day 4, there was a complete
absence of CFSE signal for both OT-I and P14 cells in all organs, indicating extensive division (data not shown). Results in A and C were analyzed by
unpaired t-test at each individual time point, with *P,0.05, **P,0.01, and ***P,0.001.
doi:10.1371/journal.pone.0011003.g003
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PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11003Figure 4. Combination immunotherapy with agonistic anti-4-1BB antibody and reactivated memory CD8 T cells. (A) C57BL/6 mice
were inoculated s.c. with E.G7 tumor cells on day 0. On day 8, adoptive transfer was performed by injecting 3610
6 reactivated memory OT-I cells i.v.
into tumor bearing mice. The agonistic anti-4-1BB antibody (3H3, 100 mg per mouse) was administrated by i.p. injection immediately following T cell
adoptive transfer and repeated once 3 days later. Average tumor growth, the number (n) of mice per group and survival of tumor bearing mice are
shown. Results are pooled from two independent experiments. (* Tumor growth curve discontinued at the time when the first animal in the group
succumbed to the disease, except for the anti-4-1BB antibody treated group in which one tumor bearer was sacrificed on day 18). Survival curves
were analyzed by the LogRank test, with **P,0.01 and ***P,0.001. (B–E) Resting memory T cells, prepared as in Figure 1, were reactivated with
peptide in the presence of 10 mg/mL of rat IgG or anti-4-1BB agonist for two days. Expression levels of the activation markers (B), Bcl-xL (C) and
granzyme B (D) were analyzed. Representative histograms from one of the two independent experiments are shown. (E) Summary of the
enhancement of Bcl-xL and granzyme B from two experiments. Median fluorescence intensity (MFI) fold differences are calculated as follows: [(MFI of
the staining of anti-4-1BB stimulated cells/MFI of the FMO of anti-4-1BB stimulated cells)]/[(MFI of the stain of the rat IgG treated cells/MFI of the FMO
of the rat IgG treated cells)]. (F) Resting memory OT-I T cells, in parallel with purified naı ¨ve OT-I CD8 T cells, were activated with peptide pulsed
splenocytes in the presence of 1 mg/mL or 10 mg/mL of rat IgG or anti-4-1BB agonist. Kinetics of the induction of granzyme B is shown. Median
fluorescence intensity (MFI) fold differences were calculated as in figure 4E.
doi:10.1371/journal.pone.0011003.g004
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11003Figure 5. Effect of systemic anti-4-1BB on the frequency and number of immune cells recovered. Mice bearing 8-day E.G7 tumors were
treated with reactivated memory OT-I T cells and anti-4-1BB or rat IgG control as in Figure 4A. On day 4, mice were sacrificed and the number of CD4,
CD8 T cells, CD11c
hi and CD11c
int CD8-negative cells (DC and macrophages), as well as transferred T cells were analyzed by flow cytometry. In the
bottom panel, recovery of WT reactivated memory OT-I T cells was compared with the 4-1BB
2/2 reactivated memory OT-I T cells, indicating that OT-I
T cells can only expand in response to anti-4-1BB when they express 4-1BB. Each data point represents an individual mouse. Data are representative
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was important in the effect of anti-4-1BB on tumor control. When
transferred T cells lacked 4-1BB, but host cells expressed 4-1BB,
we still observed an enhancement of tumor clearance by anti-4-
1BB (Fig. 6B). Thus, although 4-1BB is sufficient on the
transferred T cells for the response to anti-4-1BB, it is not
required when 4-1BB is present in the host (Fig. 6B). Although we
did not detect 4-1BB expression on the E.G7 tumor (data not
shown) and anti-4-1BB is not thought to be depleting, to rule out a
possible direct role of anti-4-1BB on tumor growth, we conducted
a control experiment in which 4-1BB-deficient mice were
implanted with the E.G7 tumor and then treated with anti-4-
1BB on day 8 and day 11 post-tumor implantation, without any T
cell transfer. Under these conditions, tumors progressed in all
groups (supplementary Figure S2). Thus anti-4-1BB has no direct
effect on the tumor and anti-4-1BB therapy can be effective if
either the transferred T cells or the host cells express 4-1BB,
implying that 4-1BB on the transferred T cells or on host cells is
sufficient for anti-4-1BB to contribute to tumor control in the
adoptive immunotherapy model. The finding that anti-4-1BB was
indeed effective when transferred cells lack but host cells express 4-
1BB, also explains the substantial effect of anti-4-1BB in tumor
control even in the absence of transferred T cells (Figure 4A).
Even though 4-1BB in the host was sufficient for the anti-4-1BB
therapy, when OT-I T cells lacked 4-1BB, they showed decreased
tumor control in the rat IgG control group compared to WT OT-I
T cells (Fig. 6B, p=0.03) suggesting that endogenous 4-1BBL can
contribute to the therapy through effects on the transferred T cells.
However, systemic addition of anti-4-1BB, through its effects in
the host, can compensate for the lack of 4-1BB on the transferred
T cells.
On which cells in the host is 4-1BB required for anti-4-1BB
induced therapy?
The above experiments suggest that 4-1BB on either the
transferred T cells or on cells in the host is sufficient for anti-4-
1BB-induced therapeutic effects in this adoptive immunotherapy
model. As both T cells and innate cells in the host were expanded
in response to anti-4-1BB treatment (Fig. 5), it was possible that
several cell types were involved. To evaluate this possibility, we
generated mixed bone marrow chimeras in which 4-1BB was only
absent from host ab T cells, but not from other cells in the host
(Fig. 7). The results show that when the transferred T cells lack 4-
1BB, anti-4-1BB dependent tumor therapy requires 4-1BB on host
ab T cells. Thus the effect of agonistic anti-4-1BB antibody on
adoptive T cell therapy requires 4-1BB expression on either
transferred or endogenous ab T cells and 4-1BB on other cell
types is dispensable for the effects of anti-4-1BB.
Discussion
Previous studies have shown the greater efficacy of central
memory over effector memory T cells in anti-cancer therapy,
attributed to their greater longevity in vivo [19,20]. On the other
hand, effector cells derived from reactivation of central memory T
cells show superior persistence compared to primary effectors in
vivo, suggesting that the combined effects of the enhanced survival
of memory T cells and the immediate cytotoxic activity of
activated effectors might be combined as a therapy [23]. The
present study supports the superiority of reactivated memory cells
over resting central memory cells in antigen-specific tumor control
in a pre-established E.G7 tumor model (Fig. 1, 2).
Analysis of T cell accumulation in the tumor, spleen and
draining LN showed that although central memory T cells had an
initial survival advantage, they rapidly disappeared, whereas the
reactivated memory cells continued to accumulate. CFSE labeling
experiments showed that although the resting memory cells were
capable of division in the tumor and draining LN, they showed less
division than their reactivated counterparts (Fig. 3). This suggested
that antigen presentation in vivo was limiting, in agreement with
previous studies showing that there is poor presentation of tumor
antigens in vivo [43,44]. The tumor microenvironment is known to
be immunosuppressive and not conducive to strong antigen
presentation [45]. Even though we used a model system in which a
foreign antigen is introduced into the tumor and we transfer 3
million T cells that have high affinity for this antigen, unless we
pre-activate the T cells there is relatively little activation of the T
cells against the pre-established tumor. Thus, although the model
may be contrived to allow us to readily follow the T cell response,
it is clearly a stringent model with aggressive tumor growth in the
absence of a highly optimized therapy.
The advantage of using reactivated memory cells, is that by
giving them their antigen ex vivo, one allows the cells to commit to
programmed expansion [37], even though antigen presentation in
the tumors may be limited. The use of reactivated memory T cells
of an irrelevant specificity confirmed this hypothesis. P14 TCR
transgenic T cells activated ex vivo, continued to divide in vivo and
accumulated at levels comparable to reactivated OT-I memory T
cells, although, as expected, they fail to control the tumor. The
failure of the adoptively transferred ‘‘resting’’ memory T cells to be
effectively reactivated in the tumor bearing host also supports the
idea that the use of ex vivo reactivated memory T cells allows tumor
control, without a requirement for the T cells to be reactivated in
the suppressive microenvironment of the tumor. These studies
suggest that for human therapy, the expansion of tumor-
infiltrating lymphocytes with Ag followed by IL-15 in vitro, and
then reactivation with Ag before reinfusion will provide improved
protection compared to using central memory T cells.
Recently, Klebanoff et al. came to a similar conclusion about
the effectiveness of in vitro reactivation of memory CD8 T cells for
cancer control [17]. In their study, effector memory T cells were
reactivated and then infused into a sublethaly irradiated tumor-
bearing host followed by systemic treatment of the mice with IL-2.
Our studies extend this result to a non-irradiated mouse and also
avoid the use of IL-2, both of which would independently
contribute to further T cell expansion. The study of Klebanoff also
showed that the pre-activation of the T cells allowed Ag-
independent release of IFNc, which in turn acted on tumor cells
to induce MHC I, which the authors proposed was key to
rendering the tumors susceptible to tumor killing. However, the
antigen specificity of these reactivated effectors was not tested [17].
In the present study, we show that activated P14 T cells, while
continuing to divide and enter the tumor, fail to have any impact
on tumor growth. Thus by comparing P14 and OT-I T cells, we
show that the property of the T cells to enter the tumor and divide
is due to their ex vivo stimulation, whereas, the tumor killing is
antigen specific and not due to T cell cytokine release alone.
Anti-4-1BB has shown promise in a number of anti-cancer
therapeutic models (reviewed in [13,14]). Consistent with a
previous study on combined use of agonistic anti-4-1BB with
of three similar experiments. Results comparing two groups were analyzed by unpaired t-test, and one-way ANOVA was used for analysis of multiple
groups in the bottom panel with *P,0.05, **P,0.01, and ***P,0.001.
doi:10.1371/journal.pone.0011003.g005
4-1BB in T Cell Tumor Therapy
PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11003Figure 6. 4-1BB on either transferred T cells or host cells is sufficient for the therapeutic effect of anti-4-1BB. (A) E.G7 tumors were
allowed to grow for 8 days in WT mice or 4-1BB-deficient mice and then inoculated with 3610
6 WT reactivated memory cells followed by two doses
of anti-4-1BB or rat IgG treatment. Average tumor growth and survival of tumor bearing mice is shown, where n indicates the number of mice per
group. Results obtained with another set of 4-1BB
2/2 mice showed a similar trend (data not shown). (B) WT mice bearing 8 day-tumors were treated
with WT or 4-1BB
2/2 reactivated OT-I memory cells followed by two doses of anti-4-1BB or rat IgG. Average tumor growth and survival curves of the
tumor bearing mice are shown. Survival curves were analyzed by the LogRank test, with *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0011003.g006
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PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e11003Figure 7. 4-1BB on non-ab T cells in the host is insufficient for anti-4-1BB mediated tumor control. Mixed bone marrow chimeras were
generated by reconstituting lethally irradiated C57BL/6 WT mice with a 4:1 mixture of TCRa2 deficient: WT or 4-1BB
2/2 bone marrow cells as
illustrated. 13 weeks post reconstitution, chimeric mice were inoculated with E.G7 cells s.c. and 8 days later were treated with reactivated 4-1BB
2/2
OT-I, followed by two doses of anti-4-1BB or rat IgG treatments as in Figure 6B. Average tumor growth and survival are shown (n=number of mice
per group). Tumor growth curves are representative of two independent experiments with 6–7 mice per group each. Survival curves include the
combined survival data from the two independent experiments.
doi:10.1371/journal.pone.0011003.g007
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provided additional effects over and above the reactivated memory
cells, largely preventing relapse and resulting in 80% cure of the 8-
day pre-established tumor (Fig. 4A); in contrast, the rat IgG
control had no effect over and above the T cells alone. It should be
pointed out however, that the major effect in our study appears to
be with the anti-4-1BB agonist antibody, which gave 60% tumor
control when used alone. The combination with T cells plus anti-
4-1BB showed a trend towards increased survival over anti-4-1BB
alone (80% survival; p=0.18). Although in our studies, it was
sufficient for 4-1BB to act on the endogenous T cells (Fig. 6, 7), in
a clinical setting, where the patient may be more immunosup-
pressed, the combination of anti-4-1BB with adoptive therapy may
be more important as compared to monotherapy with anti-4-1BB
alone.
The mechanism by which 4-1BB improves tumor control is
likely due to a combination of its ability to increase T cell survival/
expansion, as well as the ability to increase the CTL function of
the transferred and/or responding host T cells (Fig. 4C–E and
Fig. 5). In the absence of anti-4-1BB therapy, it was clear that the
reactivated memory T cells were enriched in the tumor at day 4
compared to the resting memory T cells (Fig. 3) and had a more
activated phenotype than the resting memory T cells or the
reactivated memory T cells that had gone to the spleen or draining
LN (Fig. 3B). Paradoxically, however, while anti-4-1BB increased
the number of OT-I T cells in the spleen and draining LN, we did
not observe an increase in OT-I or host T cells in the tumor after
anti-4-1BB therapy. It is worth noting that Ag-non-specific P14 T
cells accumulated at higher numbers in the tumor than the tumor
specific OT-I T cells (Fig. 3C). Therefore, it is possible that the
rapid regression of the tumors upon anti-4-1BB and adoptive T
cell therapy resulted in lower recovery of the T cells extracted for
analysis in the case of Ag-specific as compared to Ag non-specific
T cells. The finding that the Ag non-specific P14 cells are enriched
in the tumor to apparently higher levels than the Ag-specific T
cells, argues that the presence of T cells in the tumor is not a good
correlate of protection for the combined anti-4-1BB/adoptive T
cell therapy.
It was recently reported that effectors derived from naı ¨ve T cells
are superior in tumor control compared to the effectors that were
derived from central memory CD8 T cells, with apparently
enhanced proliferative potential, enhanced cytokine production, as
well as the lack of KLRG-1, a marker for proliferative senescence
[46]. Notwithstanding the difficulty of obtaining primary effectors
in large quantities from tumor infiltrating lymphocytes, the present
study shows that anti-4-1BB has a much more substantial effect on
enhancing granzyme B expression in reactivated memory T cells
as compared to its minimal effect on primary effectors (Fig. 4F).
A recent study determined that for elimination of solid tumors
in mice, it is the density of T cells (the critical T cell concentration,
or CTC) in the tumor rather than the overall effector to target
ratio that determines whether the tumor relapses or a cure is
achieved [47]. Moreover, the authors calculated that the CTC
must be maintained for at least 8 days to affect a cure. In this
regard, it is of interest that treatment with reactivated memory T
cells alone resulted in initial regression of the tumors, followed by a
relapse a few days later. In contrast, the combination of anti-4-1BB
and the reactivated memory T cells resulted in the majority of
animals achieving a cure. Moreover, it was necessary and sufficient
for either the transferred T cells or the endogenous T cells to
express 4-1BB for this effect. Thus, the ability of anti-4-1BB
antibodies to extend the lifetime of either endogenous responding
effectors or transferred T cells, may be important in maintaining
the critical T cell concentration for a cure. However, as noted
above, it is difficult to confirm the density of the CD8 T cells in the
tumor over time experimentally, as the tumors rapidly regress.
Melero et al. [12] first demonstrated the use of agonistic anti-4-
1BB antibodies as a cancer therapy and this approach has now
moved to phase I clinical trials for advanced cancers (http://www.
clinicaltrials.gov keyword CD137). Subsequent work has shown
that in some models, not only are CD4 and CD8 T cells targeted
by anti-4-1BB, but that the effect of anti-4-1BB requires the
presence of NK cells [24,26,48]. The enhancement of NK cell
cytokine production by anti-4-1BB can in turn enhance dendritic
cell function [25,27,49]. Moreover, recent studies show that
depletion of DC results in lack of efficacy of anti-4-1BB therapy
[28]. It is clear that T cells modified to express chimeric 4-1BB
signaling molecules can control tumors, arguing for direct effects of
4-1BB on CD8 T cells in cancer therapy (for example, [50–52]).
However, it was unclear in the present model, whether anti-4-1BB
was acting directly on the transferred OT-I T cells or on the host
immune system or both. The results presented here show that
although anti-4-1BB expands a number of host cell subsets,
including T cells, dendritic cells and macrophages, this function of
4-1BB is dispensable for the therapeutic effect when the
transferred T cells express 4-1BB. On the other hand, the
reciprocal experiment in which the host cells express 4-1BB, but
transferred T cells do not, also allowed anti-4-1BB to increase the
effectiveness of the adoptive immunotherapy, indicating that either
host cells or adoptively transferred T cells were necessary and
sufficient for the effect of agonist anti-4-1BB on tumor growth.
Further experiments showed that it was the host ab T cells and not
other 4-1BB expressing subsets (such as cd T cells, NK cells, or
dendritic cells) that are required for effects of anti-4-1BB on tumor
control in this model.
Recently, Narazaki et al. [53] showed in a model in which
transferred T cells are used to prevent tumor recurrence in a
rechallenge model, that for agonistic anti-4-1BB therapy, 4-1BB
was more important on the transferred T cells with lesser effects on
host cells. They went on to show that 4-1BB on radioresistant cells
was contributing to this minor effect. They suggested this could be
an NK cell or DC, but this is highly unlikely as these cells are
radiosensitive. Rather, it is possible that their observations were
due to incomplete elimination of memory T cells, which are highly
responsive to 4-1BB agonists [9] and more difficult to replace in a
radiation chimera. Our study, in contrast, clearly shows that when
transferred T cells lack 4-1BB, the absence of 4-1BB on host ab T
cells results in loss of the therapeutic effect of anti-4-1BB agonist.
Thus although 4-1BB agonists can expand many cell types, it is T
cells that are critical for the therapeutic effect, at least in this
model. This finding is consistent with a previous report that the
enhancement of T cell memory by anti-4-1BB treatment during
immunization also requires T cell intrinsic 4-1BB [54].
Agonistic anti-4-1BB antibodies are highly potent in expanding
both memory T cells as well as innate immune subsets in mice.
This has been associated with splenomegaly, and other immune
system and hematopoietic anomalies observed at doses starting at
200 mg of anti-4-1BB per mouse [30]. In our model, we used two
doses of 100 mg of the anti-4-1BB antibody per mouse and found
that this was sufficient to allow 80% mouse survival when
combined with adoptive T cell transfer. Moreover, 8/8 mice that
survived their tumors after anti-4-1BB and adoptive T cell therapy
were resistant to a second tumor challenge at day 66 and remained
healthy for at least another 60 days after initial tumor control.
Therefore, it appears that two low doses of anti-4-1BB were well
tolerated with no appearance of obvious side effects for at least
120 days post-treatment. On the other hand, in a recent study,
delivery of three consecutive weekly doses of 150 mg of a different
4-1BB in T Cell Tumor Therapy
PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e11003anti-4-1BB agonistic antibody (clone 1D8 or 2A) to mice resulted
in significant T cell mediated liver inflammation and immunopa-
thology, without control of a murine colon carcinoma [55]. Thus
the therapeutic window for 4-1BB to enhance T cell mediated
tumor control, while avoiding T cell-mediated toxicity appears to
be quite narrow. In this regard, it is of interest that alternate forms
of 4-1BB stimulation of T cells may be less toxic than systemic
administration of antibodies [56–58]. It might also be possible to
use anti-4-1BB ex vivo to enhance the survival and effector function
of the T cells prior to transfer. However, in our hands, pilot
experiments in which we used anti-4-1BB during the reactivation
of the memory T cells ex vivo did not result in the same therapeutic
effect as obtained with in vivo administration of anti-4-1BB. Thus,
this approach will likely require some optimization.
In conclusion, the results of this study extend previous studies
suggesting that for optimal CD8 T cell adoptive therapy, it is more
efficacious to reactivate memory T cells before infusion, rather
than relying on in vivo antigen presentation. Our studies show that
this in turn allows these effectors to continue to divide in vivo
independently of the presence of antigen, even in the suppressive
microenvironment of the tumor. Reactivated memory T cells in
combination with anti-4-1BB agonist therapy represent an even
more powerful combination for immunotherapy of cancer.
Remarkably our studies show that anti-4-1BB can further activate
even highly activated effectors T cells derived from central
memory T cells. We further show that the major effect of anti-4-
1BB is on the T cells and that it is necessary and sufficient for
either the adoptively transferred CD8 T cells or the host ab T cells
to express 4-1BB for the effects of anti-4-1BB to be realized.
Conversely, although other 4-1BB-expressing immune cell subsets
may contribute to the anti-tumor immune response, they do not
need to express 4-1BB for anti-4-1BB to exert its effects in this
model. As therapy with anti-4-1BB moves forward in the clinic, it
becomes more important to understand the way in which anti-4-
1BB is acting, in order to rationally design improvements and
combination therapies [15].
Materials and Methods
Mice
C57BL/6 wild type mice were purchased from Charles River
Laboratories (St. Constant, QC, Canada). 4-1BB
2/2 mice
extensively backcrossed to the C57BL/6 background have been
described [59]. OT-I mice [60], CD45.1 and Thy1.1 congenic mice
were obtained from Jackson Laboratories (Bar Harbor, Maine,
USA) and crossed to generate CD45.1 OT-I, Thy1.1 OT-I, and
Thy1.1 4-1BB
2/2 OT-I mice. OT-I transgene was detected using
anti-Va2 and anti-Vb5.1/5.2 antibodies (eBioscience, San Diego,
CA). Mice were maintained under SPF conditions in sterile
microisolators.
Ethics statement
All animal studies were approved by the University of Toronto
animal care committee in accordance with the regulations of the
Canadian Council on animal care (University of Toronto
approved protocol #20007828).
Generation of memory T cells in vitro
CD8 T cells with a central memory phenotype were generated
by culture with Ag followed by IL-15 [61,62] with modifications as
described [6]. In brief, OT-I splenocytes were stimulated with
SIINFEKL peptide (0.1 mg/ml) for 2 days, then the non-adherent
cells were rested for 1 day in fresh media (RPMI-1640 with 10%
heat-inactivated fetal calf serum, 0.03% L-glutamine, antibiotics
and 2-mercaptoethanol) then cultured in media containing 20 ng/
ml recombinant human IL-15 (R&D, Minneapolis, MN). Media
was replaced every 2 days for a total culture time of 9 days, by
which time more than 95% of the viable cells were CD8
+,V a2
+
and Vb5
+. To reactivate memory cells, irradiated (2000 rads),
SIINFEKL peptide loaded C57BL/6 splenocytes were added to
the memory cell cultures with IL-15 for the last 2 days at a ratio of
one feeder cell to one T cell. Viable cells were collected by
lympholyte gradient centrifugation (Cedarlane, Hornby, ON,
Canada). For carboxyfluorescein diacetate succinimidyl ester
(CFSE, Molecular Probes, Eugene, OR) labelling, 10
7/ml T cells
were incubated in pre-warmed PBS/2%FCS containing 5 mM
CFSE for 15 minutes at 37uC followed by 5 minutes quench on
ice, extensive washing and resuspension in PBS for adoptive
transfer. Activated memory T cells with an irrelevant Ag specificity
were generated using P14 transgenic mice [34], using the same
protocol, except that the LCMV glycoprotein peptide epitope
gp33–41[34] was used.
Analysis of T cell cytotoxicity
Viable resting or reactivated memory OT-I cells were analyzed
for the cytotoxic activity against
51Cr-labeled E.G7 or control EL-
4 target cells in a standard 4 hr
51Cr release assay, as described
[63]. The percentage of specific lysis was calculated using
the following equation: (experimental
51Cr release–spontaneous
51Cr release)/(maximum
51Cr release–spontaneous
51Cr release)6
100%=%specific lysis.
The E.G7 tumor model and immunotherapy of tumor
bearing mice
The E.G7 murine thymoma cells (American Type Culture
Collection, Manassas, VA) were freshly thawed and maintained in
media containing 0.4 mg/ml Geneticin (Invitrogen, Carlsbad,
CA). Six to ten week old mice were implanted subcutaneously on
the right flank with 5610
5 or 2610
6 E.G7 cells in PBS. Tumor
growth was monitored by measuring two perpendicular diameters
of the tumor using calipers. For adoptive transfer, a total of 3610
6
T cells in 0.2 ml PBS were injected via the tail vein into tumor
bearing mice. Where indicated, anti-4-1BB antibody (clone 3H3
[7], kindly provided by Dr. Robert Mittler, Emory University) or
the rat IgG control was administered intraperitoneally at a dose of
100 mg in 100 ml, immediately after T cell adoptive transfer and
again after 3 days.
Flow cytometry
Phenotyping of OT-I cells was carried out by surface staining
with fluorescent anti-mouse CD8a, CD44, CD62L, CD69, 4-1BB
antibodies or isotype controls (eBioscience). Single cell suspensions
of the tumor, draining lymph node (right inguinal) and spleen were
analyzed at the indicated times post-transfer. Tumor tissue was
digested with 1 mg/ml collagenase D (Roche, Indianapolis, IN),
0.1 mg/ml hyaluronidase, type V (Sigma) and 20 unit/ml DNase,
type IV (Sigma) for 1.5 hours at room temperature. OT-I cells
were identified using the Thy1.1 congenic maker. For detection of
endogenous immune subsets, cell suspensions were first blocked
with anti-FcR (eBioscience), followed by surface staining with anti-
mouse CD11c, CD11b, CD3, CD4, CD8, CD69 (eBioscience)
and NK1.1 (BD bioscience, Mountain View, CA). For intracellular
IFN-c staining, cells were restimulated with SIINFEKL for 4.5–
5 hours at 37uC in the presence of Golgi stop (BD Biosciences).
Cells were surface-stained with Cy-chrome-anti-CD8 and
APC-anti-Thy1.1 antibodies, fixed, permeabilized and stained
with PE-anti-mouse IFN-c antibody or the isotype control (BD
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vitro reactivation, viable cells were collected by lympholyte gradient
centrifugation (Cedarlane), then live cells were fixed and
permeabilized (BD Bioscience), followed by intracellular staining
with anti-Bcl-xL (SouthernBiotech, Birmingham, AL) and anti-
granzyme B antibodies (ebiosence). Data were acquired on a
FACSCalibur with the CellQuest software (BD Biosciences,) and
analyzed using FlowJo software (TreeStar Inc., CA).
Bone marrow chimeras
Bone marrow cells were obtained from femurs and tibia of WT,
TCRa
2/2, and 4-1BB
2/2 mice. C57BL/6 mice were lethally
irradiated with two doses of 550 rads, followed by reconstitution
with a 4:1 ratio of TCRa
2/2 to WT or 4-1BB
2/2 bone marrow
cells through intravenous injection at a total number of 5610
6 cells
in 200 mL volume. The 4:1 ratio was needed to ensure that the
majority of the non-T cells would be competent in expressing
4-1BB in the 4-1BB
2/2 TCRa
2/2 mixed bone marrow chimeras.
Reconstituted mice were given water supplemented with 2 mg/
mL of neomycin sulfate (Bio-Shop, Burlington, Ontario, Canada)
during the first four weeks, and they were further rested for
additional 2 months before tumor inoculation.
Supporting Information
Figure S1 Mice that received anti-4-1BB and survived the initial
tumor were fully protected against subsequent tumor challenge.
Tumor free WT survivors from the group treated with WT
reactivated OT-I followed by anti-4-1BB or rat IgG treatment
from the experiment shown in 6A were rechallenged with 26106
E.G7 tumor cells s.c. on day 60 post primary tumor inoculation
without further treatment. Average tumor growth and survival of
the naı ¨ve and rechallenged mice are shown on the left and right
panel, respectively. (n) indicates the number of mice in each group.
Survival curves were analyzed by the LogRank test, with *P,0.05,
and ***P,0.001.
Found at: doi:10.1371/journal.pone.0011003.s001 (0.16 MB TIF)
Figure S2 Lack of control of E.G7 tumor following anti-4-1BB
treatment in 4-1BB-deficient mice. 4-1BB-/- mice were inoculated
with E.G7 tumor cells on day 0, followed by two injections of anti-
4-1BB or rat IgG on day 8 and 11. Average tumor growth and
survival curves are shown on the left and right panel, respectively.
Data represent one experiment with 6 mice per group.
Found at: doi:10.1371/journal.pone.0011003.s002 (0.16 MB TIF)
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